In Vivo CAR‑T Data Release

At ASCO, Kelonia Therapeutics presented in vivo CAR‑T data that achieved a 100% response rate. The results highlight the ability to manufacture and administer the therapy more rapidly than conventional ex vivo CAR‑T treatments. The high response rate expands patient treatment options and simultaneously raises market expectations.

What Is In Vivo CAR‑T?

In vivo CAR‑T delivers genetic material directly within the patient’s body to reprogram T cells. Conventional ex vivo CAR‑T involves modifying T cells outside the body and then reinfusing them. The in vivo approach markedly reduces manufacturing complexity, lowering costs and improving accessibility.

$3.2 Billion Acquisition Rationale

Eli Lilly recently acquired Kelonia Therapeutics for $3.2 billion, and these data strengthen the strategic justification for the deal. In vivo CAR‑T diversifies Lilly’s oncology pipeline and is expected to synergize with existing anticancer agents. The acquisition aligns with Lilly’s strategy to expand its next‑generation immunotherapy portfolio.

Market and Competitive Landscape Shift

The successful data and acquisition place pressure on competitors such as Novartis and Bristol‑Myers Squibb’s CAR‑T strategies. Commercialization of in vivo CAR‑T could reduce treatment costs and production timelines, substantially improving patient access. At the same time, investors are likely to increase interest in biotech companies built on novel technologies.